comprehensive -WSS

comprehensive

author：explore 2025-08-21 06:56:06 - browse：5

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Health insurers' Q3 question: how much care are people getting?

WSS

Nobel honors Karikó and Weissman's enduring partnership

Experts study whether long Covid risk adds up with each reinfection

The biotech scorecard for Q4: 16 stock

Study points to new risk in gene therapy death of Terry Horgan

The story of mRNA: From a loose idea to a tool that may help curb Covid

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

hotspot

comprehensive

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

European officials brace for rough respiratory virus season

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The battle over the Brookhaven Landfill on Long Island

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Karikó problem: Lessons for funding basic research

Alkermes shareholders re

Do masks work? RCTs can't tell us

Bright Health sells Medicare Advantage business to Molina

The biotech scorecard for Q4: 16 stock

focus

Nobel honors Karikó and Weissman's enduring partnership

Gene therapy has helped boys walk. Can scientists keep it that way?

6 solutions to address cancer drug shortages and others

In areas with more Black doctors, Black people live longer

The Karikó problem: Lessons for funding basic research

WATCH: Why do fingernails fall off when they're damaged?

hotspot

hotspot

leisure time

knowledge